相关实验视频
Updated: Jul 20, 2025

10:20
In vitro Measurements of Tracheal Constriction Using Mice
Published on: June 25, 2012
20.8K
前缓解剂E型前列腺类受体在呼吸道光滑肌肉中的不同促收受体的功能分离
Ajay P Nayak1, Elham Javed1, Dominic R Villalba1
1Center for Translational Medicine, Jane and Leonard Korman Lung Institute, Division of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania.
概括
前列腺素E2受体EP2和EP4不同调节气道光滑肌肉收缩. EP4的激活比EP2更有效地缓解甲胆诱导的收缩,影响呼吸道光滑肌功能.
科学领域:
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
- 细胞生物学 细胞生物学
背景情况:
- 前列腺素E2 (PGE2) 通过四种E型前列腺素 (EP) 受体亚型 (EP1-EP4) 产生多种不同的生理作用.
- Gs合的EP2和EP4受体存在于气道光滑肌 (ASM),但它们在调节ASM收缩状态中的作用仍在争论中.
- 了解EP受体的功能对于开发针对性治疗呼吸道疾病至关重要.
研究的目的:
- 研究EP2和EP4受体在调节人类ASM收缩和信号传递中的不同作用.
- 为了比较EP2和EP4特异性激动剂在各种收缩刺激下放松ASM的疗效.
- 阐明参与EP受体介导的ASM收缩性调节的信号通路.
主要方法:
- 使用了特定亚型的激素ONO-259 (EP2) 和ONO-329 (EP4).
- 采用基于细胞和组织的模型:用于ASM细胞的磁扭转细胞计 (MTC) 和用于组织水平反应的精密切割肺切片 (PCLSs).
- 在组胺或甲胆 (MCh) 刺激下评估ASM收缩和信号 (VASP,HSP20,pMLC20酸化,F/G-actin比率).
主要成果:
- 与ONO-329 (EP4激动剂) 相比,ONO-329 (EP4激动剂) 在MCh合同的PCLS中表现出较强的放松,而ONO-259 (EP2激动剂) 则表现出较强的放松.
- 这两种激动剂在放松基因组胺结合的PCLS中表现出类似的疗效,表明激动剂和刺激依赖的效果.
- EP4激活 (ONO-329) 有效地逆转了PMLC20和F/G-actin比率的MCh和基因组胺诱导的变化,与MCh的EP2激活 (ONO-259) 不同.
结论:
- 与EP2受体相比,EP4受体在放松甲胆诱导的ASM收缩中起着更重要的作用.
- EP2和EP4激动剂的不同作用与肌肉素轻链酸化和actin细胞骨动态的调节有关,而不是全球PKA基质酸化.
- 研究结果表明,在调节ASM收缩性方面,包含肌肉素,组胺素和EP受体亚型的隔间信号传递.
相关概念视频
Adrenergic Receptors: ɑ Subtype
1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Adrenergic Receptors: β Subtype
1.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.7K
Antihypertensive Drugs: Types of β-Blockers
740
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
740
Adrenergic Receptors (Adrenoceptors): Classification
2.7K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
Cholinergic Receptors: Muscarinic
2.4K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
2.4K

